What You Should Know:
– CRA Health, LLC, is a breast cancer risk assessment company spinoff from Massachusetts General Hospital — a Harvard Medical School teaching hospital. Today the company delivers more than two million assessments annually to women’s imaging clinics.
– CRA software is cloud-based and tightly integrated into EHR systems. CRA receives patient information, including breast density, and returns the risk of breast cancer alongside appropriate recommendations, including whether additional imaging or genetics testing is needed according to established guidelines. Importantly, CRA has electronic interfaces established with all the major genetics companies.
– Under terms of the agreement, Volpara is paying US$18.0M to acquire all outstanding equity of CRA, with a further US$4.0M payable upon its meeting key performance targets over the next 18 months.
– The acquisition will allow Volpara to identify and deliver personalized breast care to more high-risk women across all care settings: OBGYNs, primary care providers, oncology specialists, and breast centers.
– For more than a decade, Volpara Science, a set of clinically validated algorithms that use AI to assess breast tissue composition and imaging quality, has helped more than 27 percent of all breast centers in the US optimize mammography workflow and deliver personalized care.